Millennium Management’s Monopar Therapeutics MNPR Stock Holding History

Millennium Management’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.9M	Sell	52,951 -23,723	-31%	-$1.43M	﹤0.01%	3501
2025 Q4	$5.01M	Buy	76,674 +69,340	+945%	+$5.67M	﹤0.01%	3011
2025 Q3	$599K	Sell	7,334 -7,455	-50%	-$333K	﹤0.01%	4962
2025 Q2	$529K	Sell	14,789 -45,578	-76%	-$1.66M	﹤0.01%	4873
2025 Q1	$2.2M	Buy	+60,367	New	+$2.18M	﹤0.01%	3688
2024 Q3	–	Sell	-38,860	Closed	-$145K	–	6331
2024 Q2	$145K	Buy	38,860 +384	+1%	+$1.35K	﹤0.01%	5237
2024 Q1	$131K	Buy	38,476 +32,608	+556%	+$97.2K	﹤0.01%	5510
2023 Q4	$9.98K	Buy	5,868 +2,066	+54%	+$4.18K	﹤0.01%	5741
2023 Q3	$10.8K	Sell	3,802 -2,750	-42%	-$9.61K	﹤0.01%	5753
2023 Q2	$28K	Buy	+6,552	New	+$33.5K	﹤0.01%	5585
2020 Q2	–	Sell	-2,301	Closed	-$85K	–	4436
2020 Q1	$85K	Buy	+2,301	New	+$144K	﹤0.01%	3580

Other funds holding MNPR

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management's MNPR Position: Q1 2026 in Review

Millennium Management reduced its Monopar Therapeutics (MNPR) stake by 31% in Q1 2026, selling an estimated $1.43M and leaving 52,951 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3501.

Millennium Management first reported a position in MNPR in Q1 2020 and has held it in 11 quarters since. The position peaked at $5.01M in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

Millennium Management held 52,951 shares of Monopar Therapeutics worth $2.9M as of Q1 2026.
Millennium Management sold 23,723 Monopar Therapeutics shares in Q1 2026, an estimated $1.43M.
Monopar Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3501 holding.
Millennium Management first reported a position in Monopar Therapeutics in Q1 2020 and has held it in 11 quarters since.
Millennium Management's Monopar Therapeutics position peaked at $5.01M in Q4 2025.
82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.